Journals / The Anatolian Journal of Cardiology / 2021 / Cilt: 25 - Sayı: 6

How does severe functional mitral regurgitation redefined by European guidelines affect pulmonary vascular resistance and hemodynamics in heart transplant candidates?

Pages
437–446
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Even in the updated definition of FMR with a lower threshold, severe FMR is associated with higher PVR, systolic PAP, and mean PAP and appears to have an unfavorable effect on pulmonary hemodynamics in patients with HT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Increased pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) are important prognostic factors in patients with heart transplantation (HT).
📊
Key Findings & Data:It is well known that severe mitral regurgitation increases pulmonary pressures.
💡
Conclusion & Impact:Conclusion: Even in the updated definition of FMR with a lower threshold, severe FMR is associated with higher PVR, systolic PAP, and mean PAP and appears to have an unfavorable effect on pulmonary hemodynamics in patients with HT.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Increased pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) are important prognostic factors in patients with heart transplantation (HT). It is well known that severe mitral regurgitation increases pulmonary pressures. However, the European Society of Cardiology and the 6th World Symposium of pulmonary hypertension (PH) task force redefined severe functional mitral regurgitation (FMR) and PH, respectively. We aimed to investigate the effect of severe FMR on PAP and PVR based on these major redefinitions in patients with HT. Methods: A total of 212 patients with HT were divided into 2 groups: those with severe FMR (n=70) and without severe FMR (n=142). Severe FMR was defined as effective orifice regurgitation area ≥20 mm2 and regurgitation volume ≥30 mL where the mitral valve was morphologically normal. A mean PAP of >20 mm Hg was accepted as PH. Patients with left ventricular ejection fraction ≤25% were included in the study. Results: The systolic PAP, mean PAP, and PVR were higher in patients with severe FMR than in those without severe FMR [58.5 (48.0–70.2) versus 45.0 (36.0–64.0), p<0.001; 38.0 (30.2–46.6) versus 31.0 (23.0–39.5), p=0.004; 4.0 (2.3–6.8) versus 2.6 (1.2–4.3), p=0.001, respectively]. Univariate analysis revealed that the severe FMR is a risk factor for PVR ≥3 and 5 WU [odds ratio (OR): 2.0, 95% confidence interval (CI): 1.1–3.6, p=0.009; and OR: 3.2, 95% CI: 1.5–6.7, p=0.002]. The multivariate regression analysis results revealed that presence of severe FMR is an independent risk factor for PVR ≥3 WU and presence of combined pre-post-capillary PH (OR: 2.23, 95% CI: 1.30–3.82, p=0.003 and OR: 2.30, 95% CI: 1.25–4.26, p=0.008). Conclusion: Even in the updated definition of FMR with a lower threshold, severe FMR is associated with higher PVR, systolic PAP, and mean PAP and appears to have an unfavorable effect on pulmonary hemodynamics in patients with HT.

🔖

Cite This Article

BAYRAM, Z., DOĞAN, C., ACAR, R. D., EFE, S. Ç., AKBAL, Ö. Y., YILMAZ, F., ŞENGÖR, B. G., KARADUMAN, A., UYSAL, S., KARAGÖZ, A., ÖNAL, Ç., KIRALİ, M. K., KAYMAZ, C., ÖZDEMİR, N. (2021). How does severe functional mitral regurgitation redefined by European guidelines affect pulmonary vascular resistance and hemodynamics in heart transplant candidates?. The Anatolian Journal of Cardiology, Cilt: 25 - Sayı: 6, 437–446. https://ajindex.com/articles/366645

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al.
  2. International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant 2016
  3. 1–23. [Crossref] 2. Lee SJ, Kim KH, Hong SK, Hankins S. Evaluation of a Heart Transplant Candidate. Curr Cardiol Rep 2017
  4. [Crossref] 3. Lundgren J, Söderlund C, Rådegran G. Impact of postoperative pulmonary hypertension on outcome after heart transplantation. Scand Cardiovasc J 2017
  5. 172–81. [Crossref] 4. Ghio S, Crimi G, Pica S, Temporelli PL, Boffini M, Rinaldi M, et al. Persistent abnormalities in pulmonary arterial compliance after heart transplantation in patients with combined post-capillary and pre-capillary pulmonary hypertension. PLoS One 2017
  6. e0188383. [Crossref] 5. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002
  7. 1663–8. [Crossref] 6. Harvey RM, Enson Y, Ferrer MI. A reconsideration of the origins of pulmonary hypertension. Chest 1971
  8. 82–94. [Crossref] 7. Torres-Macho J, Delgado-Jiménez JF, Sanz-Salvo J, González-Mansilla A, Sánchez-Sánchez V, Gámez-Díez S, et al. Predictors of pulmonary hypertension in patients with end-stage heart failure. Congest Heart Fail 2012
  9. 212–6. [Crossref] 8. Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013
  10. 62 (25 Suppl): D100–8. [Crossref] 9. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) 2016
  11. [Crossref] 10. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al.
  12. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017
  13. 2739–91. [Crossref] 11. Adrian L, Werner C, Laufs U. ESC Guidelines 2016 - Heart Failure. Dtsch Med Wochenschr 2017
  14. 1123–7. [Crossref] 12. Lamas GA, Mitchell GF, Flaker GC, Smith SC Jr, Gersh BJ, Basta L, et al. Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circ